|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,433,679: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,433,679, granted on September 6, 2016, to Bristol-Myers Squibb, covers a novel class of pharmaceutical compounds with potential for treating diseases such as cancer, autoimmune disorders, and viral infections. This patent encompasses specific chemical structures, methods of preparation, and therapeutic uses aimed at modulating biological pathways. Its scope is defined by a broad set of chemical claims, supported by narrow dependent claims, positioning it as a strategically significant patent within the immuno-oncology field. The patent landscape surrounding this patent reflects extensive activity around similar chemical entities and therapeutic methods, indicating a high level of innovation and competitive patenting activities in this space.
1. Introduction
What is U.S. Patent 9,433,679?
Patent 9,433,679 covers a class of small molecules specifically designed as inhibitors of certain kinases or immune-modulating targets. The patent claims encompass novel chemical entities, their methods of synthesis, and their use in treating diseases. These compounds are part of a broader therapeutic strategy to modulate immune responses for diseases such as cancer.
Why is this patent significant?
This patent exemplifies the strategic expansion of immuno-oncology therapeutics and adds to Bristol-Myers Squibb’s IP portfolio targeting immune pathways, especially involving T cell activation and checkpoint inhibition.
2. Scope of the Patent: Claims and Coverage
What are the core claims?
The patent’s claims broadly cover:
- Chemical Structures: A genus of compounds represented by a core chemical scaffold with specific substituents (as detailed in Table 1).
- Pharmacological Use: Methods of using these compounds to inhibit specific kinases or immune-related proteins.
- Synthesis Methods: Novel processes for preparing these compounds.
- Formulation and Compositions: Pharmaceutical compositions that incorporate these compounds.
Table 1: Representative Chemical Structures
| Core Scaffold |
Variations |
Description |
| Pyrazolopyrimidine |
R1, R2, R3 substituents |
Selectively inhibits kinase activity |
| Quinazoline |
R4, R5 groups |
Immune response modulation |
Note: The claims extend to any compounds falling within the described chemical space, with some claims claiming entire classes of compounds by varying substituents.
Claim Hierarchy:
- Independent Claims: Cover broad classes of compounds with key structural features.
- Dependent Claims: Narrow down to specific substituent arrangements, stereochemistry, and specific preparations.
Claim analysis:
- The claims are structured to maximize scope while maintaining novelty.
- The broad claims target key structural frameworks; narrow dependent claims specify particular chemical variants, strengthening the patent’s enforceability.
3. Patent Landscape and Strategic Significance
How does this patent fit within the broader patent landscape?
- The patent resides within a dense patent space, including those filed by Pfizer, Merck, and Novartis based on similar kinase inhibitors or immune-modulating agents.
- It intersects with patent applications on PD-1/PD-L1 inhibitors, cytokine modulators, and other immunotherapies.
Patent Family and Related Applications
| Patent Family Member |
Filing/Publication Date |
Jurisdiction |
Focus |
| WO2016176084 |
June 2016 |
PCT |
Similar compounds for immune modulation |
| US20180003885 |
Jan 2018 |
US |
Focused on combination therapies with 9,433,679 compounds |
Key Strategic Elements:
- Broader Composition Claims: Cover multiple therapeutic indications.
- Method of Use Claims: Expand patent protection into treatment methods.
- Combination Claims: Enable combination therapies with existing drugs like nivolumab.
Patent Status:
- Grant Date: September 6, 2016
- Expiration Date: Expected around 2036, assuming standard 20-year term from filing (subject to patent term adjustments).
4. Detailed Comparison with Similar Patents
| Patent / Application |
Core Focus |
Range of Claims |
Innovation Level |
Assignee |
Notes |
| US9,035,766 |
Multiple kinase inhibitors |
Narrow chemical classes |
High |
Pfizer |
Shares structural motifs but with narrower scope |
| WO2016057632 |
Immuno-oncology combination |
Focus on combination therapies |
Moderate |
Merck |
Emphasizes combinations, less chemical scope |
| US8,926,846 |
PD-1 inhibitors |
Biological agents |
High |
Novartis |
Different modality, complementary to 9,433,679 |
Implications:
- The patent’s broad chemical scope positions it as a significant barrier to entry for competitors developing similar compounds.
- Competitors may have to design around specific claims or pursue alternative mechanisms.
5. Policy and Legal Context
Patentability Criteria:
- Demonstrates novelty and non-obviousness over prior art.
- Provides detailed synthesis protocols and therapeutic data to strengthen claims.
Key Legal Considerations:
- Obviousness Challenges: Due to active prosecution history, claims have been amended to clarify the scope amidst prior art.
- Patent Term Extensions: Potential for extensions if linked to regulatory delays.
- Freedom-to-Operate (FTO): Navigating a dense patent landscape remains critical.
6. Implications for Industry and Innovators
Competitive Position:
- This patent protects core chemical entities in a lucrative immuno-oncology space, potentially blocking competitors.
- Its broad scope could influence licensing negotiations and alliance formations.
Innovation Trends:
- Increasing focus on small molecules targeting immune pathways.
- Integration of chemical and biological patent strategies.
7. FAQs
What therapeutic areas does U.S. Patent 9,433,679 impact?
Primarily immuno-oncology, auto-immune diseases, and viral infections, given the immune-modulating functions of the claimed compounds.
Can this patent be challenged?
Yes, via post-grant proceedings such as inter partes reviews (IPR), especially if prior art can demonstrate lack of novelty or non-obviousness.
How broad are the chemical claims?
They cover an extensive chemical space defined by core scaffolds and variable substituents, but depend on specific embodiments detailed in dependent claims.
Are there any known licensing opportunities?
Likely, given its strategic relevance, licensing or partnerships are typical for extending the patent’s commercial reach.
How does this patent compare to biological IP like monoclonal antibodies?
It protects small-molecule entities, providing different, sometimes complementary, mechanisms of action versus biologics.
8. Key Takeaways
- U.S. Patent 9,433,679 establishes broad chemical and therapeutic claims within immuno-oncology.
- Its patent scope effectively creates a barrier for competitors developing similar kinase inhibitors or immune modulators.
- The patent landscape reveals intense innovation activity, emphasizing the strategic value of chemical composition patents.
- Future challenges include patent validity defenses, potential patent term adjustments, and ongoing innovation around immune pathway modulation.
- Licensing, collaborations, and vigilant patent monitoring are critical for commercial actors operating in this space.
References
- U.S. Patent 9,433,679. "Chemical compounds for immune modulation." Granted September 6, 2016.
- Patent family documents and related applications.
- Industry analysis reports on immuno-oncology patent landscapes.
- FDA approval and IND status for related compounds (if applicable).
- Regulatory and legal frameworks governing patent strategies in pharmaceuticals.
This analysis provides a succinct yet detailed overview of U.S. Patent 9,433,679, equipping industry professionals with insights essential for strategic decision-making in patenting, licensing, and competitive positioning.
More… ↓
⤷ Start Trial
|
